on Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Gains New Investor: Dr. Thomas Gutschlag
Viromed Medical AG, a medical technology company based in Pinneberg, announced the addition of Dr. Thomas Gutschlag as a new investor. Dr. Gutschlag, known for his role as founder and Chairman of the Supervisory Board of Deutsche Rohstoff AG, has purchased 100,000 shares in Viromed from CEO Uwe Perbandt’s holdings.
Dr. Gutschlag expressed enthusiasm for Viromed’s cold plasma technology, highlighting its potential to revolutionize medical applications in wound healing, intensive care, and air disinfection. CEO Uwe Perbandt welcomed the investment, acknowledging Gutschlag’s capital market expertise and support for the company.
Viromed specializes in cold atmospheric plasma (CAP), a painless treatment method that activates healing processes and inactivates harmful pathogens. With its recent stock market listing, Viromed plans to expand CAP applications in medicine to harness further growth.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Viromed Medical AG news